- Home
- TORO vs NRXP Comparison
TORO vs NRXP Comparison
Compare TORO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TORO | NRXP |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 151.1M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TORO | NRXP |
|---|---|---|
| Price | $5.96 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 25.0K | ★ 619.7K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $1.65 |
| 52 Week High | $8.50 | $5.06 |
Technical Indicators
Market Signals| Indicator | TORO | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 45.06 |
| Support Level | $4.87 | $3.09 |
| Resistance Level | $6.15 | $3.62 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 6.35 | 43.82 |
Price Performance
Historical ComparisonAbout TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.